Five Prime Therapeutics, Inc. Enters Into Antibody Research Collaboration Agreement With Adimab LLC.

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SOUTH SAN FRANCISCO, Calif., Jan. 9, 2014 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today announced a sponsored research collaboration agreement with Adimab, LLC, a leader in discovery of monoclonal and bispecific antibodies. Five Prime will provide multiple targets to Adimab for the discovery and optimization of therapeutic monoclonal antibodies initially focused in cancer immunotherapy.

Help employers find you! Check out all the jobs and post your resume.

Back to news